Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 3/20 | 0.58 |
| ▸ | RXRA | P19793 | 2/20 | 0.57 |
| ▸ | RARB | P10826 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | ALAD | P13716 | 1/20 | 0.46 |
| ▸ | HNF4A | P41235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1498034 | 0.88 | RXRB (0.70) | RXRBRXRARARBMCL1HNF4A | |
| SCHEMBL29771992 | 0.88 | RXRB (0.70) | RXRBRXRARARBMCL1HNF4A | |
| Hydrochloric Acid SCHEMBL4365452 | 0.86 | RXRB (0.68) | RXRBRXRARARBMCL1HNF4A | |
| Hydrochloric Acid SCHEMBL9150803 | 0.86 | RXRB (0.68) | RXRBRXRARARBMCL1HNF4A | |
| SCHEMBL10024251 | 0.85 | MCL1 (0.54) | NPC1RAB9AMCL1TSHRCASP1 | |
| SCHEMBL8840571 | 0.85 | MCL1 (0.65) | RXRBRXRARARBMCL1SMN1; SMN2 | |
| SCHEMBL8960674 | 0.85 | RXRB (0.62) | RXRBRXRARARBMCL1SMN1; SMN2 | |
| SCHEMBL13522888 | 0.85 | ACMSD (0.63) | RXRBRXRARARBMCL1SMN1; SMN2 | |
| SCHEMBL122517 | 0.85 | ACMSD (0.63) | RXRBRXRARARBMCL1SMN1; SMN2 | |
| SCHEMBL29926573 | 0.85 | ACMSD (0.63) | RXRBRXRARARBMCL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20180327367-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | WUXI APPTEC CO., LTD (CN) | 2018-11-15 | — | — | US | disclosed |
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | FAS SECURED CREDITORS HOLDCO, LLC | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327367-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | RXRB 2425/4885RXRA 3420/4885RARB 1554/4885 |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | RXRB 2425/4885RXRA 3420/4885RARB 1554/4885 |
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | LCAT, DGAT2, SOAT2 | RXRB 3198/4885RXRA 3267/4885RARB 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.